Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
17
SNTI Quote, Financials, Valuation and Earnings
Last price:
$0.93
Seasonality move
:
-21.45%
Day range:
$0.82 - $0.95
52-week range:
$0.80 - $5.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.27x
P/B ratio:
3.01x
Volume:
220.1K
Avg. volume:
316.1K
1-year change:
-78.52%
Market cap:
$24.5M
Revenue:
--
EPS (TTM):
-$3.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
-- | -$0.31 | -- | -29.56% | $11.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$298.6M | $0.20 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.4B | $2.63 | 110.49% | -58.59% | $479.79 |
|
IBIO
iBio, Inc.
|
$33.3K | -$0.05 | -83.34% | -91.89% | $4.72 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
VOR
Vor Biopharma, Inc.
|
-- | -$1.14 | -- | -282.69% | $44.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
$0.93 | $11.50 | $24.5M | -- | $0.00 | 0% | 3.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
IBIO
iBio, Inc.
|
$2.42 | $4.72 | $54.4M | -- | $0.00 | 0% | 106.96x |
|
SVRA
Savara, Inc.
|
$5.30 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
VOR
Vor Biopharma, Inc.
|
$13.16 | $44.60 | $90M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
78.76% | -0.774 | 81.25% | 1.03x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
IBIO
iBio, Inc.
|
5.55% | 0.321 | 19.65% | 8.21x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
|
VOR
Vor Biopharma, Inc.
|
-0.14% | 24.439 | 0.92% | 9.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
-$904K | -$16.9M | -79.41% | -173.17% | -- | -$9.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
IBIO
iBio, Inc.
|
-$189K | -$6M | -75.48% | -88.23% | -5951% | -$5.7M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
VOR
Vor Biopharma, Inc.
|
-$2K | -$28.1M | -- | -- | -- | -$53.9M |
Senti Biosciences, Inc. vs. Competitors
-
Which has Higher Returns SNTI or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of 25.76%. Senti Biosciences, Inc.'s return on equity of -173.17% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SNTI or ACAD?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1136.16%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that Senti Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Senti Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SNTI or ACAD More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock SNTI or ACAD?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or ACAD?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Senti Biosciences, Inc.'s net income of -$18.1M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns SNTI or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of 20.1%. Senti Biosciences, Inc.'s return on equity of -173.17% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About SNTI or ALNY?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1136.16%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that Senti Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is SNTI or ALNY More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock SNTI or ALNY?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or ALNY?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Senti Biosciences, Inc.'s net income of -$18.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns SNTI or IBIO?
iBio, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of -5720%. Senti Biosciences, Inc.'s return on equity of -173.17% beat iBio, Inc.'s return on equity of -88.23%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M IBIOiBio, Inc.-189% -$0.11 $59.3M -
What do Analysts Say About SNTI or IBIO?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1136.16%. On the other hand iBio, Inc. has an analysts' consensus of $4.72 which suggests that it could grow by 95.04%. Given that Senti Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Senti Biosciences, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 IBIOiBio, Inc.5 0 0 -
Is SNTI or IBIO More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.829%.
-
Which is a Better Dividend Stock SNTI or IBIO?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or IBIO?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of $100K. Senti Biosciences, Inc.'s net income of -$18.1M is lower than iBio, Inc.'s net income of -$5.7M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 106.96x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M IBIOiBio, Inc.106.96x -- $100K -$5.7M
-
Which has Higher Returns SNTI or SVRA?
Savara, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SNTI or SVRA?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1136.16%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 104.01%. Given that Senti Biosciences, Inc. has higher upside potential than Savara, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 SVRASavara, Inc.6 0 0 -
Is SNTI or SVRA More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock SNTI or SVRA?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or SVRA?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns SNTI or VOR?
Vor Biopharma, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Vor Biopharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M VORVor Biopharma, Inc.-- -$121.63 -$2.2B -
What do Analysts Say About SNTI or VOR?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1136.16%. On the other hand Vor Biopharma, Inc. has an analysts' consensus of $44.60 which suggests that it could grow by 238.91%. Given that Senti Biosciences, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 VORVor Biopharma, Inc.5 1 0 -
Is SNTI or VOR More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vor Biopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SNTI or VOR?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Vor Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or VOR?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Vor Biopharma, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is higher than Vor Biopharma, Inc.'s net income of -$812.7M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Vor Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus -- for Vor Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M VORVor Biopharma, Inc.-- -- -- -$812.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
